https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46783 Wed 30 Nov 2022 13:21:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53428 Wed 28 Feb 2024 14:45:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35624 Wed 27 Sep 2023 15:37:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38598 Wed 22 Mar 2023 18:40:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29808 Wed 20 Jan 2021 17:35:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31495 Wed 20 Jan 2021 17:25:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37298 Wed 20 Jan 2021 16:51:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38502 71BM ternary blend show efficiencies up to 10.2% (device active area 0.88 cm²), which is the highest value reported to date (for in-air slot-die-coated devices). This is achieved through ink modifications and optimizations as well as electrode and active layer compositional optimizations, leading to an impressive efficiency retention of 0.86 compared to the in-literature optimized small-scale devices.]]> Wed 19 Apr 2023 11:52:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38684 Wed 17 Apr 2024 10:09:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46173 Wed 13 Mar 2024 19:12:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46539 Wed 13 Mar 2024 19:10:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54107 Wed 13 Mar 2024 19:08:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52852 Wed 13 Mar 2024 19:04:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46509 Wed 13 Mar 2024 11:23:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34788 Wed 13 Mar 2024 09:37:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49030 Wed 07 Feb 2024 16:41:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40408 Wed 07 Feb 2024 15:29:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52821 Wed 07 Feb 2024 14:59:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53512 Wed 07 Feb 2024 14:37:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39072 Wed 04 May 2022 15:08:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54359 Tue 20 Feb 2024 16:26:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36711 Tue 16 Apr 2024 15:47:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42846 Tue 14 Nov 2023 14:55:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49266 Tue 14 Nov 2023 14:55:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49249 Tue 14 Nov 2023 14:52:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46452 −1 drove a density reduction of ∼ 20% over 25 RF periods.]]> Tue 14 Nov 2023 14:51:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49267 Tue 14 Nov 2023 14:50:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54129 Tue 06 Feb 2024 11:35:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46886 –1) compared to the nonporous S-CN (167.9 mA h g^–1) and g-C₃N₄ (5.4 mA h g^–1), highlighting the pivotal roles of the highly ordered mesoporous structure and S-doping in enhancing the electrochemical functionality of carbon nitride as an anode material for SIBs.]]> Tue 06 Dec 2022 09:52:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38461 50=30 nM and 400-fold selective c.f. MCF10A (normal breast tissue). Acetamide moiety modification (13 a-g) to introduce additional hydrophobicity was favoured with MCF-7 breast cancer cell activity enhanced at 1.3 nM. Other analogues were potent against the HT29 colon cancer cell line at 23 nM. Textbook SAR data was observed in the MCF-7 cell line, in an MTT assay, via the ortho (17 a), meta (17 b) and para (13 f). The amino alcohol -OH moiety was pivotal, but no stereochemical preference noted. But, these data did not fit our homology modelling expectations. Aberrant MTT ((3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) screening results and metabolic interference confirmed by sulforhodamine B (SRB) screening. Interfering analogues resulted in 120 and 80-fold CYP1A1 and CYP1A2 amplification, with no upregulation of SULT1A1. This is consistent with activation of the AhR pathway. Piperidine per-deuteration reduced metabolic inactivation. 3-OH / 4-OH piperidine analogues showed differential MTT and SRB activity supporting MTT assay metabolic inactivation. Data supports piperidine 3-OH, but not the 4-OH, as a CYP substrate. This family of β-amino alcohol substituted 3,4-dichlorophenylacetonitriles show broad activity modulated via the AhR pathway. By SRB analysis the most potent analogue was 23 b, (Z)-3-(4-(3-(4-phenylpiperidin-1-yl)-2-hydroxypropoxy)phenyl)-2-(3,4-dichlorophenyl)-acrylonitrile.]]> Thu 18 Nov 2021 10:32:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38506 Thu 18 Nov 2021 10:12:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38606 2 or a chronic health condition recruited from general practices was conducted. The arms included (1) BBL-GP, a web-based intervention augmented with an in-person diet and physical activity consultation; (2) a single clinician-led group, Lifestyle Modification Program (LMP); and (3) a web-based control. The primary outcome was the Australian National University Alzheimer Disease Risk Index Short Form (ANU-ADRI-SF). Results: Baseline assessments were conducted on 128 participants. A total of 125 participants were randomized to 3 groups (BBL-GP=42, LMP=41, and control=42). At immediate, week 18, week 36, and week 62 follow-ups, the completion rates were 43% (18/42), 57% (24/42), 48% (20/42), and 48% (20/42), respectively, for the BBL-GP group; 71% (29/41), 68% (28/41), 68% (28/41), and 51% (21/41), respectively, for the LMP group; and 62% (26/42), 69% (29/42), 60% (25/42), and 60% (25/42), respectively, for the control group. The primary outcome of the ANU-ADRI-SF score was lower for the BBL-GP group than the control group at all follow-ups. These comparisons were all significant at the 5% level for estimates adjusted for baseline differences (immediate: difference in means -3.86, 95% CI -6.81 to -0.90, P=.01; week 18: difference in means -4.05, 95% CI -6.81 to -1.28, P<.001; week 36: difference in means -4.99, 95% CI -8.04 to -1.94, P<.001; and week 62: difference in means -4.62, 95% CI -7.62 to -1.62, P<.001). Conclusions: A web-based multidomain dementia risk reduction program augmented with allied health consultations administered within the general practice context can reduce dementia risk exposure for at least 15 months. This study was limited by a small sample size, and replication on a larger sample with longer follow-up will strengthen the results.]]> Thu 18 Nov 2021 09:43:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43339 Thu 15 Sep 2022 15:11:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43264 Thu 08 Feb 2024 10:41:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36973 Thu 08 Feb 2024 10:40:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47329 Thu 02 May 2024 15:36:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44363 Mon 29 Jan 2024 18:53:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39326 −2) and eh-IDTBR (18.3 mJ m⁻²). This article is the first report of a flipped nanoparticle core–shell morphology comprising an NFA-rich shell for the miniemulsion synthesis route. The composition of the shells and cores was able to be controlled by the differential mismatch in the surface energy of the donor and acceptor materials, with ΔG_surface > 0, ΔG_surface = 0, and ΔG_surface < 0 for acceptor core–donor shell, molecularly intermixed, and acceptor shell–donor core, respectively. Accordingly, we introduce an entirely overlooked new figure of merit (FoM) for customizing nanoparticulate colloidal inks: tunable surface energy of non-fullerene-based semiconductors. The establishment of this FoM opens up electroactive material design to a wide range of functional printing applications with varying device and ink structure requirements, thereby reshaping the nanoengineering toolkit for waterborne colloidal dispersions and hence printed electronics.]]> Mon 29 Jan 2024 18:52:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53394 Mon 29 Jan 2024 18:51:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40978 Mon 29 Jan 2024 18:51:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43858 Mon 29 Jan 2024 18:49:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39743 Mon 29 Jan 2024 18:49:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48009 Mon 29 Jan 2024 18:45:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53644 Mon 29 Jan 2024 18:43:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38390 Mon 29 Jan 2024 18:42:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39837 Mon 29 Jan 2024 18:41:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45396 Mon 29 Jan 2024 18:39:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38257 Mon 29 Jan 2024 18:39:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45714 Mon 29 Jan 2024 18:38:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46331 Mon 29 Jan 2024 18:37:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39011 Mon 29 Jan 2024 18:37:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52029 Mon 29 Jan 2024 18:35:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50649 Mon 29 Jan 2024 18:35:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47036 Mon 29 Jan 2024 18:34:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49164 Mon 29 Jan 2024 18:34:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48177 Mon 29 Jan 2024 18:34:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52378 Mon 29 Jan 2024 18:33:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50301 Mon 29 Jan 2024 18:28:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52064 Mon 29 Jan 2024 18:26:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51146 Mon 29 Jan 2024 18:24:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51629 Mon 29 Jan 2024 18:23:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48938 Mon 29 Jan 2024 18:22:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47195 Mon 29 Jan 2024 18:05:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38476 n = 2136, 96.4%), low back pain without specific etiology (n = 1,863, 84.1%), and chronic duration (n = 947, 42.8%). The quality of trials improved over time; however, most were at risk of bias. Less than half of the trials concealed allocation to intervention (n = 813, 36.7%), used intention-to-treat principles (n = 778, 35.1%), and blinded assessors (n = 810, 36.6%), participants (n = 174, 7.9%), and therapists (n = 39, 1.8%). These findings did not vary by the type of therapy. Conclusion: Most trials that test physical therapy interventions for low back pain have methodological limitations that could bias treatment effect estimates. Greater attention to methodological features, such as allocation concealment and the reporting of intention-to-treat effects, would improve the quality of trials testing physical therapy interventions for low back pain.]]> Mon 29 Jan 2024 18:05:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47640 Mon 29 Jan 2024 18:04:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44254 Mon 29 Jan 2024 18:04:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46090 Mon 29 Jan 2024 18:03:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42380 Mon 29 Jan 2024 18:01:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38311 8H₄K₂O₁₂Sb₂, Sb₂S₃, Sb₂O₃ and Sb₂O₃ nanoparticles) were evaluated during 120 days ageing time. A black soil (BS) with approximately 12% organic matter (OM) and a red soil (RS) with less than 1% OM were amended with 1000 mg Sb kg⁻¹ of different Sb compounds and subjected to single extractions with distilled (DI) water, 2M HNO₃, Simplified Bioaccessibility Extraction Test (SBET) and a modified Community Bureau of Reference (BCR) sequential extraction method. The results revealed that there are substantial variations in dissolution rate of various Sb sources, depending upon soil type and Sb compound. The amounts of DI water extractability of Sb during the incubation time varied between <1% and 2%, whereas HNO₃ extractable fractions and Sb bioaccessibility at the end of ageing time ranged between about 1%-3% and <1%–9% of the total Sb, with maximum bioaccessibility observed in BS contaminated with C₈H₄K₂O₁₂Sb₂. The residual and labile fractions accounted for 77–93% and 0.1–4% of the total Sb, respectively, indicating that Sb is mostly associated with recalcitrant fractions of the soils. The results of single and sequential extraction studies revealed that source of Sb, ageing time and soil properties can greatly affect the bioavailability of Sb in soils. The findings of this research provide a deeper understanding of the potential risks associated with Sb compounds and highlights the role of site-specific considerations for improving the robustness of toxicity guidelines and long-term management of Sb contaminated sites.]]> Mon 29 Jan 2024 18:01:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38436 Mon 29 Jan 2024 18:01:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38437 Mon 29 Jan 2024 18:01:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45543 4 or Fe-N₄ planar configuration. The developed Ni-N₄/GHSs/Fe-N,₄ Janus material exhibits excellent bifunctional electrocatalytic performance, in which the outer Fe-N₄ clusters dominantly contribute to high activity toward the oxygen reduction reaction (ORR), while the inner Ni-N₄ clusters are responsible for excellent activity toward the oxygen evolution reaction (OER). Density functional theory calculations demonstrate the structures and reactivities of Fe-N₄ and Ni-N₄ for the ORR and OER. The Ni-N₄/GHSs/Fe-N₄ endows a rechargeable Zn–air battery with excellent energy efficiency and cycling stability as an air-cathode, outperforming that of the benchmark Pt/C+RuO₂ air-cathode. The current work paves a new avenue for precise control of single-atom sites on carbon surface for the high-performance and selective electrocatalysts.]]> Mon 29 Jan 2024 18:00:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42484 Mon 29 Jan 2024 17:58:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40999 Mon 29 Jan 2024 17:56:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44528 Mon 29 Jan 2024 17:54:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38870 Mon 29 Jan 2024 17:54:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48453 Mon 29 Jan 2024 17:52:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39152 2·6H₂O) by using a nucleating agent - flake graphite. A super absorbent polymer (SAP) was also used as a thickener to prevent segregation of CaCl₂·6H₂O during phase transition. The combined method of thermogravimetric analysis/differential thermal analysis (TGA-DTA) was firstly proposed to evaluate the segregation of inorganic PCM innovatively. The results showed that using 0.5 wt% flake graphite not only eliminated the supercooling of CaCl₂·6H₂O, but also improved its thermal conductivity for better thermal performance. The results of Fourier-transform infrared spectroscopy (FT-IR) and scanning electron microscope (SEM) demonstrated that the flake graphite did play an important role on the crystallization of CaCl₂·6H₂O. Numerical simulation demonstrated that using modified CaCl₂·6H₂O within walls of buildings in Hong Kong and Changsha are economically feasible with the payback periods of 18.3 years and 8.4 years respectively.]]> Mon 29 Jan 2024 17:51:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43095 Mon 29 Jan 2024 17:50:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44063 −1; at this speed, the car consumes the least amount of energy (around 137 MJ when travelling a distance of 100 km). All the speeds less than the optimum speed will consume more energy; the same is true when the speed is increased over the optimum. For the second application using water pumps, it was found that a 1.1 kW pump is the most efficient at pumping a specific amount of water, and using higher or lower rated pumps will consume higher energy levels but correspondingly will reduce the time required to perform the same application. This research emphasised the concept that time can save energy, which is not yet covered in the literature as time value of energy when time is not an essential aspect and can be delayed without affecting the main tasks.]]> Mon 29 Jan 2024 17:50:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38535 Mon 29 Jan 2024 17:49:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38651 Mon 29 Jan 2024 17:49:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38401 Mon 29 Jan 2024 17:48:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38406 Mon 29 Jan 2024 17:48:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46344 −1 mgCAT⁻¹ and faradaic efficiency (FE) of 11.6% are achieved using our antimonene nanosheets. Theoretical calculations suggest that the oxidized species of antimonene act as the active catalytic sites for the NRR process. This work opens up a new avenue towards the development of 2D electrocatalysts for clean energy.]]> Mon 29 Jan 2024 17:48:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38394 Mon 29 Jan 2024 17:47:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38396 Mon 29 Jan 2024 17:47:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38260 9-tetrahydrocannabinol (∆⁹-THC). Evidence is emerging for the therapeutic benefits of cannabis in the treatment of neurological and neurodegenerative diseases, with potential efficacy as an analgesic and antiemetic for the management of cancer-related pain and treatment-related nausea and vomiting, respectively. An increasing number of preclinical studies have established that ∆⁹-THC can inhibit the growth and proliferation of cancerous cells through the modulation of cannabinoid receptors (CB1R and CB2R), but clinical confirmation remains lacking. In parallel, the anti-cancer properties of non-THC cannabinoids, such as cannabidiol (CBD), are linked to the modulation of non-CB1R/CB2R G-protein-coupled receptors, neurotransmitter receptors, and ligand-regulated transcription factors, which together modulate oncogenic signalling and redox homeostasis. Additional evidence has also demonstrated the anti-inflammatory properties of cannabinoids, and this may prove relevant in the context of peritumoural oedema and the tumour immune microenvironment. This review aims to document the emerging mechanisms of anti-cancer actions of non-THC cannabinoids.]]> Mon 29 Jan 2024 17:45:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41684 Mon 29 Jan 2024 17:43:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39018 2DS₂-VA scheme, were calculated. Factors associated with AF were assessed using logistic regression. Results: From 2000 to 2015, a total of 1827 women with AF were identified. AF prevalence increased every year as women aged from 2.71% (95% CI 1.62%–3.80%) in 2000 among women aged 74–79 years to 24.83% (95% CI = 23.23%–26.44%) in 2015 among women aged 89–94 years. The incidence proportion remained constant (between 3% and 5%) throughout the study period. Sedentary lifestyle (OR = 1.24, 95% CI = 1.04–1.49), hypertension (OR = 1.24, 95% CI = 1.09–1.42), arthritis (OR = 1.24, 95% CI = 1.09–1.41), heart attack (OR = 1.62, 95% CI = 1.18–2.24), and angina (OR = 1.39, 95% CI = 1.14–1.70) were independently associated with AF. Mean CHA₂DS₂-VA score for women with AF was 3.43 (SD ± 1.23). Conclusions: The prevalence of AF reported in Australian women is among the highest compared to previous estimations from other countries and regions. According to the findings, about one in four women over the age of 90 years had AF. These women were also at high risk of stroke. This has significant public health implications especially with changing demographics of increase in the aging population. Further research is required on understanding how women with AF are treated in Australia and their health outcomes.]]> Mon 29 Jan 2024 17:43:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44893 Mon 24 Oct 2022 15:42:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44581 Mon 17 Oct 2022 14:19:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41851 Mon 15 Aug 2022 10:38:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44158 Mon 10 Oct 2022 09:38:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44152 Mon 10 Oct 2022 09:31:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41162 Fri 23 Feb 2024 10:25:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38524 Fri 22 Oct 2021 11:25:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47217 Fri 16 Dec 2022 10:16:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44461 Fri 14 Oct 2022 09:07:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38948 Fri 11 Mar 2022 12:45:18 AEDT ]]>